Gramicidin

Jump to: navigation, search
1GRM.gif
Gramicidin
Systematic (IUPAC) name
Bacillus brevis gramicidin D
Identifiers
CAS number 1405-97-6
ATC code R02AB30
PubChem  ?
DrugBank BTD00036
Chemical data
Formula C99H140N20O17 
Mol. mass 1882.3 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

WikiDoc Resources for

Gramicidin

Articles

Most recent articles on Gramicidin

Most cited articles on Gramicidin

Review articles on Gramicidin

Articles on Gramicidin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Gramicidin

Images of Gramicidin

Photos of Gramicidin

Podcasts & MP3s on Gramicidin

Videos on Gramicidin

Evidence Based Medicine

Cochrane Collaboration on Gramicidin

Bandolier on Gramicidin

TRIP on Gramicidin

Clinical Trials

Ongoing Trials on Gramicidin at Clinical Trials.gov

Trial results on Gramicidin

Clinical Trials on Gramicidin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Gramicidin

NICE Guidance on Gramicidin

NHS PRODIGY Guidance

FDA on Gramicidin

CDC on Gramicidin

Books

Books on Gramicidin

News

Gramicidin in the news

Be alerted to news on Gramicidin

News trends on Gramicidin

Commentary

Blogs on Gramicidin

Definitions

Definitions of Gramicidin

Patient Resources / Community

Patient resources on Gramicidin

Discussion groups on Gramicidin

Patient Handouts on Gramicidin

Directions to Hospitals Treating Gramicidin

Risk calculators and risk factors for Gramicidin

Healthcare Provider Resources

Symptoms of Gramicidin

Causes & Risk Factors for Gramicidin

Diagnostic studies for Gramicidin

Treatment of Gramicidin

Continuing Medical Education (CME)

CME Programs on Gramicidin

International

Gramicidin en Espanol

Gramicidin en Francais

Business

Gramicidin in the Marketplace

Patents on Gramicidin

Experimental / Informatics

List of terms related to Gramicidin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Gramicidin is a heterogeneous mixture of six antibiotic compounds, Gramicidins A, B and C, making up 80%, 6%, and 14% respectively[1], all of which are obtained from the soil bacterial species Bacillus brevis and called collectively Gramicidin D. Gramicidin D are linear pentadecapeptides; that is chains made up of 15 amino acids[2]. This is in contrast to Gramicidin S which is a cyclic peptide chain. Gramicidin is active against Gram-positive bacteria, except for the Gram-positive bacilli, and against select Gram-negative organisms, such as Neisseria bacteria. Its therapeutic use is limited to topical application as it induces hemolysis in lower concentrations than bacteria cell death thus cannot be administered internally. The exterior epidermis is composed of dead cells, thus applying it to the surface of the skin will not cause harm. It is used primarily as a topical antibiotic and is one of the three constituents of consumer antibiotic Neosporin Ophthalmic Solution. In 1939 the French-American microbiologist René Dubos isolated the substance tyrothricin and later showed that it was composed of two substances, gramicidin (20%) and tyrocidine (80%). These were the first antibiotics to be manufactured commercially.

Composition and Structure

Gramicidin is composed of the general formula: formyl-L-X-Gly-L-Ala-D-Leu-L-Ala-D-Val-L-Val-D-Val-L-Trp-D-Leu-L-Y-D-Leu-L-Trp-D-Leu-L-Trp-ethanolamine

X and Y depend upon the gramicidin molecule. There exists valine and isoleucine variants of all three gramicidin species and 'X' can be either. Y determines which is which; in the place of Y Gramicidin A contains Tryptophan, B contains Phenylalanine and C contains Tyrosine. Also note the alternating stereochemical configurations (in the form of D and L) of the amino acids: this is vital to the formation of the β-helix.

The chain assembles inside of the hydrophobic interior of the cellular lipid bilayer to form a β-helix. The helix itself is not long enough to span the membrane but it dimerizes to form the elongated channel needed to span the whole membrane.

The structure of gramicidin head-to-head dimer in micelles and lipid bilayers was determined by solution and solid state NMR. In organic solvents and crystals, this peptide forms different types of non-native double helices.

Pharmacological Effect

Gramicidin's bactericidal activity is a result of increasing the permeability of the bacterial cell wall allowing inorganic monovalent cations (e.g. H+) to travel through unrestricted, thereby destroying the ion gradient between the cytoplasm and the extracellular environment.

That gramicidin D functions as a channel was demonstrated by Hladky and Haydon, who investigated the unit conductance channel. In general, gramicidin channels are ideally selective for monovalent cations and the single-channel conductances for the alkali cations are ranked in the same order as the aqueous mobilities of these ions. Divalent cations like Ca-2+ block the channel by binding near the mouth of the channel. So it is basically impermeable to divalent cations. It also excludes anions. Cl- in particular is excluded from the channel because its hydration shell is thermodynamically stronger than that of most monovalent cations. The channel is permeable to most monovalent cations, which move through the channel in single file. The channel is filled with about six water molecules, almost all of which must be displaced when an ion is transported. Thus, ions moving through the gramicidin pore carry along a single file of water molecules. Such a flux of ion and water molecules is known as flux coupling. In the presence of a second type of permeable ion, the two ions couple their flux as well. Like Valinomycin and Nonactin, the gramicidin channel is selective for potassium over sodium but only slightly so. It has a permeability ration of 2.9. It is impermeable to anions but there are conditions under which some anion permeation may be observed. Its ability to bind and transport cations is due to the presence of cation-binding sites in the channel. Specifically, there are two such binding sites, one strong and the other weak.

References

  1. A. S. Bourinbaiar and C. F. Coleman Arch Virol (1997) 142: 2225-2235
  2. Biopolymers (Peptide Science), Vol. 51, 129–144 (1999): http://www3.interscience.wiley.com/cgi-bin/abstract/62500357/ABSTRACT Burkhart, Brian M. (1999), "Gramicidin D conformation, dynamics and membrane ion transport", Biopolymers 51: 129, DOI 10.1002/(SICI)1097-0282(1999)51:2<129::AID-BIP3>3.0.CO;2-Y
  • Ketchem RR, Lee KC, Huo S, Cross TA (1996). "Macromolecular structural elucidation with solid-state NMR-derived orientational constraints". J. Biomol. NMR 8 (1): 1–14. doi:10.1007/BF00198135. PMID 8810522.
  • Townsley LE, Tucker WA, Sham S, Hinton JF (2001). "Structures of gramicidins A, B, and C incorporated into sodium dodecyl sulfate micelles". Biochemistry 40 (39): 11676–86. doi:10.1021/bi010942w. PMID 11570868.

External links



de:Gramicidin it:Gramicidina


Navigation WikiDoc | WikiPatient | Popular pages | Recently Edited Pages | Recently Added Pictures

Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs

Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link Here
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
Linked-in.jpg
Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox
In other languages